Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $210 to $220.
Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $210 to $220.